Metastatic Breast Cancer - Pipeline Review, H2 2015

Metastatic Breast Cancer - Pipeline Review, H2 2015

Code: GMDHC7200IDB | Published: Dec-2015 | Pages: 966 | Global Markets Direct
Price :
$2,000.00
USD

* Required Fields

$2,000.00

Details

Metastatic Breast Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Metastatic Breast Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Breast Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
Amarna Therapeutics B.V.
Ambrx, Inc.
Amgen Inc.
AngioGenex, Inc.
Aphios Corporation
arGEN-X BV
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
BIOCAD
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Campus Technologies Freiburg GmbH
CASI Pharmaceuticals Inc.
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Curadis GmbH
Curaxys, S.L.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Dompe Farmaceutici S.p.A.
Dr. Reddys Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
EOS Biosciences, Inc.
Epirus Biopharmaceuticals, Inc.
Etubics Corporation
Eureka Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Galileo Research s.r.l.
Genelux Corporation
Genentech, Inc.
Genor BioPharma Co., Ltd.
Glycotope GmbH
GTx, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hetero Drugs Limited
Hospira, Inc.
Immune Design Corp.
Immunomedics, Inc.
Immupharma Plc
Imugene Limited
Inbiopro Solutions Pvt. Ltd.
Incyte Corporation
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kancera AB
Karyopharm Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Mabion SA
MacroGenics, Inc.
MandalMed, Inc.
Meabco A/S
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
MetaStat, Inc.
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
Mycenax Biotech Inc.
NanoCarrier Co., Ltd.
NantKwest, Inc.
Natco Pharma Limited
Nektar Therapeutics
NewLink Genetics Corporation
Nippon Kayaku Co., Ltd.
Northwest Biotherapeutics, Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Pharmaceuticals, Inc.
Paras Biopharmaceuticals Finland Oy
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Polyphor Ltd.
Prima BioMed Ltd.
Puma Biotechnology, Inc.
Radius Health, Inc.
Samyang Holdings Corporation
Sanofi
Seattle Genetics, Inc.
Shanghai Henlius Biotech Co., Ltd.
Starpharma Holdings Limited
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Syndax Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Theracrine, Inc.
Transgene Biotek Limited
Vaxil Bio Therapeutics Ltd.
Verastem, Inc.
Vertex Pharmaceuticals Incorporated
VioQuest Pharmaceuticals, Inc.
Wilex AG
WntResearch AB
ZIOPHARM Oncology, Inc.
Zymeworks Inc.
Zyngenia, Inc.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients